| __timestamp | CymaBay Therapeutics, Inc. | Geron Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 16758000 |
| Thursday, January 1, 2015 | 8871000 | 17793000 |
| Friday, January 1, 2016 | 9645000 | 18761000 |
| Sunday, January 1, 2017 | 12387000 | 19287000 |
| Monday, January 1, 2018 | 14381000 | 18707000 |
| Tuesday, January 1, 2019 | 19238000 | 20893000 |
| Wednesday, January 1, 2020 | 17425000 | 25678000 |
| Friday, January 1, 2021 | 23040000 | 29665000 |
| Saturday, January 1, 2022 | 25116000 | 43628000 |
| Sunday, January 1, 2023 | 51953000 | 69135000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, from 2014 to 2023, CymaBay Therapeutics, Inc. and Geron Corporation have shown significant shifts in their Selling, General, and Administrative (SG&A) expenses. CymaBay's SG&A expenses surged by over 500%, from approximately $8 million in 2014 to over $51 million in 2023. Meanwhile, Geron Corporation's expenses increased by around 300%, reaching nearly $69 million in 2023 from $17 million in 2014. This upward trend reflects strategic investments in operational growth and market expansion. Notably, both companies experienced their most substantial expense increases between 2021 and 2023, indicating a period of aggressive scaling. These financial insights provide a window into the strategic priorities of these biotech firms, highlighting their commitment to innovation and market presence.
Selling, General, and Administrative Costs: Novo Nordisk A/S vs CymaBay Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Catalent, Inc. and CymaBay Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Walgreens Boots Alliance, Inc. or Geron Corporation
Selling, General, and Administrative Costs: Exelixis, Inc. vs Geron Corporation
Jazz Pharmaceuticals plc or Geron Corporation: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs Geron Corporation
Operational Costs Compared: SG&A Analysis of Alkermes plc and Geron Corporation
Axsome Therapeutics, Inc. vs Geron Corporation: SG&A Expense Trends
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs PTC Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs Novavax, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Geron Corporation and Xencor, Inc.